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ABSTRACT
Surgery is the most frequent treatment in women with symptomatic uterine fibroids. A new medical
approach with ulipristal acetate (UPA) has been suggested. The aim of this study was to provide data on
effectiveness and safety of UPA in premenopausal women with symptomatic uterine fibroids. This was a
multicenter retrospective cohort study. Data on all consecutive premenopausal women with symptomatic
uterine fibroids referred to three Italian centers were included in a dedicated merged database. Women
aged 18–55 years, who received pharmacologic therapy with UPA 5mg orally once a day, were included
in the study. The primary outcome was the percentage of women who underwent surgery after UPA
treatment. One hundred and forty-two premenopausal women with uterine fibroids were included in this
study. The mean age was 43.2 years. Eighty-one (57.0%) of 142 women treated with UPA had only med-
ical treatment and did not undergo surgery. Surgical treatment occurred in 70, 23, 32, and 8% of the
women who received one course, two courses, three courses, or four courses, of UPA treatment, respect-
ively. The incidence of side effects was 10.6%. The effectiveness and safety of repeated UPA treatment
courses in reducing number of women requiring surgery is confirmed by real-world data.
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Introduction
Uterine fibroids, myomas, or leiomyomas are benign tumors, the
most common of the female reproductive tract. Careful follow-
up can be performed in asymptomatic women, or in those with
mild symptoms [1–3].
The most frequent symptoms of uterine fibroids are abnormal
vaginal bleeding, pain, and abdominal pressure [3,4].
Prophylactic therapy is usually not performed, except in cases of
submucosal fibroids in women desiring pregnancy in order to
reduce the risk of early pregnancy loss [4].
The goal of treating symptomatic women is to reduce symp-
toms [5,6], and surgery is the most frequent treatment [1,7–9].
Recently, a new medical approach with Selective Progesterone
Receptor Modulators (SPRMs) has been suggested [9]. Short-term
SPRMs administration led to improved quality of life, reduced
menstrual bleeding with higher rates of amenorrhea compared to
placebo [10]. Ulipristal acetate (UPA), a SPRM administered
orally, is able to control excessive bleeding and to reduce signifi-
cantly the size of the fibroids after 12weeks treatment, and fur-
ther with repeated intermittent courses [11]. Generally, patients,
with heavy menstrual bleeding and myomas, selected and
randomized in controlled trials do not fully represent the ‘real
world’ because to reduce variability and to ensure quality of data
adherence to a well-characterized protocol is usually requested.
Therefore, the aim of this study was to provide data on effect-
iveness and safety of UPA in premenopausal women with symp-
tomatic uterine fibroids
Methods
This was a multicenter, observational, retrospective cohort study.
Data on all consecutive premenopausal women with an ultra-
sound diagnosis of uterine fibroids, referred for myomectomy to
three Italian Hospitals (Endoscopic Hospital, Freestanding Palagi
Unit, Florence; University of Naples Federico II, Naples; and
University of Cagliari, Cagliari) from October 1, 2014 to May 31,
2017 were included in a dedicated merged database.
Women aged 18–55 years, with symptomatic uterine fibroids,
who received pharmacologic therapy with UPA, UPA 5mg orally
once a day were included in the study. Exclusion criteria were
(a) postmenopausal women; (b) women received additional treat-
ment (e.g. uterine artery embolization); and (c) women pre-
treated with gonadotropin releasing hormone (GnRH) agonists,
combined hormonal contraception, or progestogens.
Outcomes
The primary outcome was the percentage of women undergoing
surgical procedures after UPA treatment. The secondary out-
comes were changes in fibroids volume before and after the
pharmacologic treatment assessed by ultrasound, and changes in
menstrual flow. For hysteroscopic surgery, we also planned to
assess ease of delineating surgical planes between the myoma
and the myometrium pseudocapsula. Surgeons performed two
reports at the end of the surgical operations, assessing (1)
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difficulty in identifying the cleavage plan (a score from 0, no dif-
ficulty, to 10, highest difficulty); (2) the consistency of the
myoma (a score from 0, soft, to 10 hard). Questionnaires were
also performed regarding the difficulties in the execution of
the intervention (0¼ very bad and 10¼ excellent), regarding
the quality of the hysteroscopic vision (0¼ none and
10¼maximum), regarding difficulty in dilating the cervical neck
(0¼ absent intraoperative bleeding and 10¼ very abundant
bleeding). Patient satisfaction and adverse treatment effects were
also evaluated.
Statistical analysis
The estimated sample to be included in the study was about 150
patients to generate a 95% confidence interval with an amplitude
of 0.17 when the sample proportion is 0.5 (calculations using the
exact Clopper–Pearson formula). Given the observational and
retrospective nature of the study, data on some variables are
understandably incomplete, except for the variables related to the
primary objective. Furthermore, given the observational and
retrospective study design, the analysis was mainly descriptive.
Appropriate statistical, parametric (Student t) and non-paramet-
ric (Wicoxon and McNemar) statistical tests were used to evalu-
ate some study objectives and to compare data before and after
medical and/or surgical therapy. Adverse events that emerged
during drug therapy have also been reported descriptively (fre-
quency, severity, duration, and measures are taken).
Results
Study population
During the study period 142 symptomatic premenopausal
women with uterine fibroids, which met the inclusion criteria,
were included in the study and analyzed.
The mean age was 43.2 years, ranging from 26 to 54 years.
The mean BMI was 24, ranging from 17.5 to 35.1. The main fea-
tures of menstrual bleeding were: regular menstrual cycle in
71.3%, irregular in 21.3%, other (polymororrhea, absent, and oli-
gomenorrhea) 7.4%; menstrual bleeding duration: prolonged
(>8 d) in 75.6%, normal (4.5–8.0 d) in 22%, short 2.4%; men-
strual bleeding entity: abundant in 96.3%, other (normal and
low) 3.7%; hemoglobin: median value 9.00mg/dL (Table 1).
At the first visit 46 patients (92%) complained of pelvic pain,
reported with a severity of pain (VAS 0–10) of 0–3 in 18.9% of
cases, of 4–6 in 45.2%, of 7–10 in 35.9%, of which 9.4% was
unbearable pain (VAS 10). The average pain severity score
was 5.3.
The number of fibroids per patient at the first ultrasound was
1 myoma in 64% of cases, 2–3 myomas in 26% of cases, 4–6
myomas in 10%. The type of myomas, according to the FIGO
classification, was for 21% submucosal, for 56% intramural, for
15% subserosal. The overall average volume of myomas at the
first pretreatment visit was 98.6 cm3 (43 cm3 of median).
Regarding duration of UPA treatment, out of 142 women
treated with 5mg/die UPA, 60 (42.3%) received UPA for 1
course (3months); 47 (33.1%) for 2 courses, 22 (15.5%) for 3
courses and 13 (9.2%) for 4 courses (Table 2).
Primary outcome
Eighty-one (57.0%) of 142 women treated with UPA had only
medical treatment and did not undergo surgery. Surgical
treatment occurred in 70, 23, 32, and 8% of the women who
received one cycle, two cycles, three cycles, or four cycles, of
treatment, respectively (Table 3).
Secondary outcomes
During the study period, a variable number of ultrasounds
(range 2–6) were made to the patients. Of the patients, 65% had
two ultrasound reports, and 35% of the women had three or
more scans. Regarding the effects of therapy on the volume of
myomas in all patients who did not undergo surgery between
the first and last ultrasound (n¼ 132): the average/median value
of the volumes went from 102.4/43.6 to 83.9/28.3 cm3, with an
average reduction of 18% and a median of 35% (p< .01).
With regard to the intensity of the menstrual bleeding, in 85
women, 80 of them (94.1%) reported at the first visit an abun-
dant bleeding (Table 1); at the last evaluation, only 22 patients
(25.9%) still had abundant bleeding, 3 (3.5%) a poor bleeding,
and the others 60 (70.6%) reported a normal bleeding (p< .01).
With regard to the duration of the menstrual bleeding, in 102
women, 78 (76.5%) reported in the first visit a prolonged bleed-
ing (menstrual bleeding >8 d); at the last visit, only 17 (16.7%)
patients reported a prolonged bleeding and patients with normal
menstrual bleeding duration went from 21.6 to 81.4% (p< .01).
Hemoglobin levels improved during treatment: in 72 of 142
women whose data were reported, about 50% had the median
hemoglobin level less than 9mg/dL at baseline; after UPA treat-
ment only 25% of women had hemoglobin level less than
12mg/dl.
Safety and tolerability
The following adverse effects were reported in 15 patients
(10.6%), during treatment with UPA: 6.3% of experienced head-
ache patients, 3.5% reported swelling/abdominal pain, 1.4% hot
flushes and, 0.7% complained mood swing. All adverse events
were mild to moderate (7 mild and 8 moderate), no severe event
Table 1. Characteristics of the included women at the first visit.
Characteristics Values N¼ patients
Age (years) 43.2 ± 8.4 142
BMI 24.0 ± 3.7 50
Irregular menstrual cycle 29 (21.3%) 136
Menstrual flow >8 d 96 (75.6%) 127
Menstrual flow abundant 105 (96.3%) 109
Hemoglobin mg/dL 9.00 ± 2.1 72
Data are presented as mean ± standard deviation or as number (percentage).
Table 3. Number of women requiring surgery according to number of UPA
courses received.
Overall
(n¼ 142)
1 course
UPA
(n¼ 60)
2 courses
UPA
(n¼ 47)
3 courses
UPA
(n¼ 22)
4 courses
UPA
(n¼ 13)
Surgery 61 (43.0%) 42 (70.0%) 11 (23.4%) 7 (31.8%) 1 (7.7%)
Table 2. Number of UPA courses received by patients analyzed.
All
patients
1 course
UPA
2 courses
UPA
3 courses
UPA
4 courses
UPA
N. Pts/% n¼ 142
(100%)
n¼ 60
(42.3%)
n¼ 47
(33.1%)
n¼ 22
(15.5%)
n¼ 13
(9.2%)
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was detected. Of the women, 97.6% were satisfied with the
treatment.
Patient satisfaction score on therapy was reported in 81
patients. The acceptability of the therapy was good, in fact with
a score ranging from 0 to 10 (0¼ no satisfaction and
10¼maximum satisfaction), 97.6% of the patients declared a
score > of 5 in terms of overall satisfaction, 14.8% a score
between 9 and 10 and 49.4% a score between 7 and 8.
Hysteroscopic surgery outcomes
During hysteroscopic surgery, the separation of G1–G2 myomas
from the myometrium was usually easy to perform using cold
loops. All procedures were ended by slicing technique. The oper-
ation was considered complete when the fasciculate fibers of the
myometrium (fovea) were visualized.
The endometrial aspect was hypotrophic in 84.6%, prolifera-
tive in 7.7%, with confluent cysts with a flaccid aspect in 3.8%,
secretory 3.8%.
Questionnaires regarding the difficulty in identifying the
cleavage plan were performed for 25 patients. With a score from
0 to 10 (0¼ none and 10¼maximum) the average score was
lower than 5 (score 4.4).
Questionnaires regarding the consistency of the myoma were
performed for 27 women. With a score from 0 to 10 (0¼ soft
and10¼ hard) the average score was 5.5, with no cases lower
than 5.
Overall, in 96.4% there were no difficulties in the execution
of the intervention, with an average score ¼ 7.5 (0¼ very bad
and 10¼ excellent) regarding the quality of the hysteroscopic
vision; the average score was 3.6 (0¼ none and 10¼maximum)
regarding difficulty in dilating the cervical neck; the average
score was 4 (0¼ absent intraoperative bleeding and 10¼ very
abundant bleeding) regarding intra-surgical bleeding.
Discussion
Uterine fibroids are the most common benign uterine tumors in
women, occurring in about 20–40% of those in fertility age.
Current management includes surgical, either myomectomy or
hysterectomy, or non-surgical approach [12,13]. Non-surgical
approach includes medical treatment with hormonal or non-hor-
monal therapies, and radiological procedures, including uterine
artery embolization [1]. Among medical treatments, SPRMs are a
new class of drugs. SPRMs include UPA 5mg tablets, [14] cur-
rently approved for preoperative treatment and for intermittent
treatment of moderate to severe symptoms of uterine fibroids in
adult women of reproductive age. Due to its anti-progesterone
properties, UPA has been shown to cause a reduction in uterine
bleeding and fibroid size, leading to symptomatic improvement
in women with fibroids who are planned for surgery [14].
Despite proven efficacy for fibroid symptoms, data on the effect
of UPA in clinical practice is limited. Available literature focuses
mainly on surgical outcomes of myomectomy [15]. Moreover,
the effects of long-term treatment of UPA have not been exten-
sively investigated in clinical practice so far [16].
Our study, evaluating efficacy and safety of UPA in real life,
in women with symptomatic uterine fibroids, showed that treat-
ment with UPA is an effective therapy in reducing number of
women requiring surgery. The efficacy increases increasing num-
bers of UPA courses, up to four courses. In our cohort, surgical
treatment occurred in 70, 23, 32, and 8% of the women who
received one course, two courses, three courses, or four courses,
of treatment, respectively. Therefore, repeated intermittent
administration of UPA seems to maximize its potential benefits
in terms of complete avoidance of surgery in more than 50% of
women. The incidence of side effects was 10.6%, with headache
being the most common one. Our study also showed that UPA
was associated with significant reduction in myoma volume and
improved menstrual symptoms. Moreover, hysteroscopic myo-
mectomy was not negatively affected by presurgical treatment
with UPA; in fact, 96.4% of the surgical operators did not report
any difficulty in performing surgery.
Study limitations included the small sample size, but part of
the reason of limited patients treated with repeated courses,
depends on late introduction of the second indication of the
drug in Italy in September 2016, incomplete electronic hospital
records and the short follow-up. The retrospective non-random-
ized study design is the major shortcoming of the study.
In conclusion, the findings of this real-world study demonstrate
the efficacy of more than one course of 5mg UPA in bleeding
control and fibroid shrinking and further confirm the use of
repeated intermittent administration of UPA in avoiding surgery.
Therefore, therapy with UPA may be offered as a safe and effect-
ive alternative to standard surgical approach in premenopausal
women with symptomatic uterine fibroids. Large well-designed
randomized controlled trials are needed to confirm our findings
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